Aktienanalyse zu CytoMed Therapeutics Ltd (GDTC)GDTCCytoMed Therapeutics Ltd

CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

CytoMed Therapeutics Ltd (GDTC) is not a good buy right now due to its significant downward trends and poor financial metrics. The current price is $0.92, which is down 33.81% year-to-date and 54.11% over the past year. Additionally, the stock has a negative P/E ratio of -1.91 and a forward P/E of 0, indicating a lack of profitability and future earnings potential. The RSI is at 46.19, suggesting the stock is neither overbought nor oversold, but the overall trend is negative. The main risk is the 5-day change of -10.68%, indicating a recent sharp decline in value.